pharmaceutical-engineering section insights 
ISPE
DECEMBER 1, 2022
The next track session on ‘ Future Proofing Hybrid Inspections ’ by Jenny Hantzinikolas, (Director, Inspection Section, Manufacturing Quality Branch, Australian Department of Health (TGA), provided an insightful look into how regulators have had to pivot to an online model seemingly overnight. Global Head Technology & Engineering.
ISPE
MAY 10, 2023
Sanat’s organization oversees a complex and large network of manufacturing, commercialization, and distribution operations across four different platforms of pharmaceuticals, vaccines, biologics, and animal health with over 20,000 employees in over 22 countries. Articles can be 400 to 1,000 words. Please submit to msanford@ispe.org NA NA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
OCTOBER 5, 2023
Driven by the increasing need for safe and efficient medical devices and drug delivery systems, the pharmaceutical polymers / medical grade polymers domain is advancing significantly. Some innovations related to pharmaceutical / medical grade polymers have been mentioned in the following sections.
ISPE
JULY 10, 2023
In sections where we applied ChatGPT for example cases, we indicate this as such: The question or remark from us is labeled as Authors. Second, ChatGPT provides a very broad, high-level overview of possible activities and tasks for which it may be used in the pharmaceutical industry. Specific aspects of pharmaceutical roles (e.g.,
ISPE
SEPTEMBER 11, 2023
This article presents relevant insights on the current regulatory and technical landscape for decentralized manufacturing, with select examples of current applications, and discusses perspectives on evolving and adapting the current regulations to meet future capabilities.
ISPE
JULY 6, 2023
This article provides a review on the current state of CM implementation, offers insights into life cycle management and regulatory aspects, and explains how a data- and knowledge-centric approach to risk management can help CM achieve its full potential. In 2021, CONTINUUS Pharmaceuticals secured a$69.3 billion US in 2021 to $1.9
ISPE
MARCH 6, 2023
Challenges for Net Zero Carbon Pharmaceutical Manufacturing Trudy Patterson Mon, 03/06/2023 - 12:40 Features March / April 2023 Challenges for Net Zero Carbon Pharmaceutical Manufacturing Keith M. Sixth Assessment Report: Climate Change 2021: The Physical Science Basis.” Finalized 9 August 2021. C global warming scenario.
Expert insights. Personalized for you.
52 
Let's personalize your content